Literature DB >> 12774005

The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis.

Steven W M Olde Damink1, Rajiv Jalan, Nicolaas E P Deutz, Doris N Redhead, Cornelis H C Dejong, Paula Hynd, Rosy A Jalan, Peter C Hayes, Peter B Soeters.   

Abstract

Upper gastrointestinal (UGI) bleeding in cirrhosis is associated with enhanced ammoniagenesis, the site of which is thought to be the colon. The aims of this study were to evaluate interorgan metabolism of ammonia following an UGI bleed in patients with cirrhosis. Study 1: UGI bleed was simulated in 8 patients with cirrhosis and a transjugular intrahepatic portasystemic stent-shunt (TIPSS) by intragastric infusion of an amino acid solution that mimics the hemoglobin molecule. We sampled blood from the femoral artery and a femoral, renal, portal, and hepatic vein for 4 hours during the simulated bleed and measured plasma flows across these organs. Study 2: In 9 cirrhotic patients with an acute UGI bleed that underwent TIPSS insertion, blood was sampled from an artery and a hepatic, renal, and portal vein, and plasma flows were measured. Study 1: During the simulated bleed, arterial concentrations of ammonia increased significantly (P =.002). There was no change in ammonia production from the portal drained viscera, but renal ammonia production increased 6-fold (P =.008). In contrast to an unchanged ammonia removal by the liver, a significant increase in muscle ammonia removal was observed. Study 2: In patients with an acute UGI bleed, ammonia was only produced by the kidneys (572 [184] nmol/kg bw/min) and not by the splanchnic area (-121 [87] nmol/kg bw/min). In conclusion, enhanced renal ammonia release has an important role in the hyperammonemia that follows an UGI bleed in patients with cirrhosis. During this hyperammonemic state, muscle is the major site of ammonia removal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774005     DOI: 10.1053/jhep.2003.50221

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Treatment of hepatic encephalopathy: it's not lactulose.

Authors:  Debbie L Shawcross; Rajiv Jalan
Journal:  BMJ       Date:  2004-07-10

Review 2.  Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.

Authors:  Amit S Seyan; Robin D Hughes; Debbie L Shawcross
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

3.  Role of ammonia and inflammation in minimal hepatic encephalopathy.

Authors:  D L Shawcross; G Wright; S W M Olde Damink; R Jalan
Journal:  Metab Brain Dis       Date:  2007-03       Impact factor: 3.584

Review 4.  Dietary and nutritional indications in hepatic encephalopathy.

Authors:  Manuela Merli; Oliviero Riggio
Journal:  Metab Brain Dis       Date:  2008-12-04       Impact factor: 3.584

Review 5.  The treatment of hepatic encephalopathy.

Authors:  Marsha Y Morgan; A Blei; K Grüngreiff; R Jalan; G Kircheis; G Marchesini; O Riggio; Karin Weissenborn
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 6.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

7.  Current concepts in the pathophysiology and management of hepatic encephalopathy.

Authors:  R Todd Frederick
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

Review 8.  Roles of renal ammonia metabolism other than in acid-base homeostasis.

Authors:  I David Weiner
Journal:  Pediatr Nephrol       Date:  2016-05-12       Impact factor: 3.714

Review 9.  New technologies - new insights into the pathogenesis of hepatic encephalopathy.

Authors:  Luisa Baker; Bernard Lanz; Fausto Andreola; Javier Ampuero; Anisha Wijeyesekera; Elaine Holmes; Nicolaas Deutz
Journal:  Metab Brain Dis       Date:  2016-09-30       Impact factor: 3.584

Review 10.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.